Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$-257.0K-107.68%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jian Irish
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 113
- Beta
- 0.68
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -3.57
Financials
Revenue
$-257.0K-107.7%Net Income
$-27.48MEBITDA
$-26.22MFree Cash Flow
$-19.64MEPS (diluted)
$-0.73Shares Outstanding (diluted)
37.66M+535.1%Operating Expenses
$28.52MCash & Debt
$120.66MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $25.21M | $-87.87M | $-2.36 |
| 2024 | $52.30M | $-78.06M | $-2.09 |
| 2023 | $44.76M | $-68.25M | $-1.82 |
| 2022 | $17.20M | $-43.59M | $-1.16 |
| 2021 | $243.0K | $-21.44M | $-3.62 |
Valuation
MGXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+25.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·35d ago·Neutral
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference EMERYVILLE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D.
View source ↗ - Newsseekingalpha.com·46d ago·Neutral
MGX Resources Limited (MTGRY) Q4 2026 Earnings Call Prepared Remarks Transcript MGX Resources Limited (MTGRY) Q4 2026 Earnings Call Prepared Remarks Transcript
View source ↗ - Newszacks.com·56d ago·Negative
Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue Estimates Metagenomi Therapeutics (MGX) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to a loss of $0.54 per share a year ago.
View source ↗
Earnings
Tue, Nov 10(in 5 weeks)
Consensus estimate $-0.64 per share
Typical surprise -1.7% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.73 vs $-0.55miss
- Mon, May 11$-0.61 vs $-0.60miss
- Thu, Mar 5$-0.60 vs $-0.58miss
- Tue, Nov 11$-0.55 vs $-0.60beat
- Tue, Aug 12$-0.54 vs $-0.68beat
- Tue, May 13$-0.68 vs $-0.62miss
Estimates and results for MGX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MGX officers and directors.
- Bought
- $13.0m
- Sold
- $112k
4 trades
26 trades
- Reid Laurencebought
- Reid Laurencebought
- Wein Matthewsold
- Irish Jiansold
- Wapnick Pamelasold
- Wapnick Pamelasold
- Irish Jiansold
- Wein Matthewsold
70 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MGX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.